Polyamine and EIF5A hypusination downstream of c-Myc confers targeted therapy resistance in BRAF mutant melanoma

Abstract Background BRAF inhibitors are widely employed in the treatment of melanoma with the BRAF V600E mutation. However, the development of resistance compromises their therapeutic efficacy. Diverse genomic and transcriptomic alterations are found in BRAF inhibitor resistant melanoma, posing a pr...

Full description

Bibliographic Details
Published in:	Molecular Cancer
Main Authors:	Byung-Sun Park, Heeju Jeon, Yeonseo Kim, Haejin Kwon, Ga-Eun Choi, Sung-Gil Chi, Hyun-Mee Park, Hyunbeom Lee, Tackhoon Kim
Format:	Article
Language:	English
Published:	BMC 2024-07-01
Subjects:	Melanoma BRAF Vemurafenib Polyamine Hypusination c-Myc
Online Access:	https://doi.org/10.1186/s12943-024-02031-w

Similar Items

Role of Polyamines and Hypusine in β Cells and Diabetes Pathogenesis
by: Abhishek Kulkarni, et al.
Published: (2022-04-01)

Hypusination, a Metabolic Posttranslational Modification of eIF5A in Plants during Development and Environmental Stress Responses
by: Péter Pálfi, et al.
Published: (2021-06-01)

Hypusination in intestinal epithelial cells protects mice from infectious colitis
by: Alain P. Gobert, et al.
Published: (2024-12-01)

Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma
by: Azad Saei, et al.
Published: (2018-09-01)

Half Way to Hypusine—Structural Basis for Substrate Recognition by Human Deoxyhypusine Synthase
by: Elżbieta Wątor, et al.
Published: (2020-03-01)

In Silico Studies of Novel Vemurafenib Derivatives as BRAF Kinase Inhibitors
by: Teresa Żołek, et al.
Published: (2023-07-01)

Renal Ischemia Tolerance Mediated by eIF5A Hypusination Inhibition Is Regulated by a Specific Modulation of the Endoplasmic Reticulum Stress
by: Nicolas Melis, et al.
Published: (2023-01-01)

COP1 Deficiency in BRAF<sup>V600E</sup> Melanomas Confers Resistance to Inhibitors of the MAPK Pathway
by: Ada Ndoja, et al.
Published: (2025-06-01)

BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma
by: Rimas V Lukas, et al.
Published: (2018-04-01)

Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling
by: Yufan Tan, et al.
Published: (2021-06-01)

eIF5A hypusination, boosted by dietary spermidine, protects from premature brain aging and mitochondrial dysfunction
by: YongTian Liang, et al.
Published: (2021-04-01)

Durable Remission After Targeted Therapy in BRAF V600E–Mutant Metastatic Colorectal Cancer: Case Report
by: Daniel A. Fox, et al.
Published: (2025-01-01)

AMD1 promotes breast cancer aggressiveness via a spermidine-eIF5A hypusination-TCF4 axis
by: Ruocen Liao, et al.
Published: (2024-04-01)

Sarcoid-like Granulomatous Intraocular Inflammation Caused by Vemurafenib Treatment for Metastatic Melanoma
by: Hilal Eser Öztürk, et al.
Published: (2020-01-01)

Application of GC7 to reduce hypusination via inhibiting deoxyhypusine synthase in Arabidopsis thaliana seedlings exposed salt stress
by: Ágnes Szepesi, et al.
Published: (2023-12-01)

Analysis of the effect of hypusination in myeloid cells on colitis and colitis-associated cancer
by: Alain P. Gobert, et al.
Published: (2024-07-01)

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer
by: Matthias Lang, et al.
Published: (2023-03-01)

PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation
by: Andrea Marranci, et al.
Published: (2023-04-01)

Targeted Therapy With Vemurafenib in Brazilian Children With Refractory Langerhans Cell Histiocytosis: Two Case Reports and Review of Literature
by: Klerize Anecely de Souza Silva, et al.
Published: (2024-08-01)

By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma
by: Mehrdad Payandeh, et al.
Published: (2012-03-01)

By what way Physician can Enhance Outcomes in Patients with metastatic Malignant Melanoma
by: Mmohammad Erfan Zare, et al.
Published: (2012-01-01)

New K50R mutant mouse models reveal impaired hypusination of eif5a2 with alterations in cell metabolite landscape
by: Chad R. Schultz, et al.
Published: (2023-03-01)

Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines
by: Jingjing Xiao, et al.
Published: (2018-06-01)

DHPS‐Mediated Hypusination Regulates METTL3 Self‐m6A‐Methylation Modification to Promote Melanoma Proliferation and the Development of Novel Inhibitors
by: Jing‐si Guo, et al.
Published: (2024-09-01)

MelCher5k/<i>BRAF</i><sup>+</sup> subcutaneous human melanoma xenograft with CD20 expression
by: I. N. Mikhaylova, et al.
Published: (2025-06-01)

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study
by: Yuankai Shi, et al.
Published: (2024-06-01)

Vemurafenib induces senescence in acute myeloid leukemia and myelodysplastic syndrome by activating the HIPPO signaling pathway: implications for potential targeted therapy
by: Qiao Zhou, et al.
Published: (2024-01-01)

Vemurafenib induces a noncanonical senescence-associated secretory phenotype in melanoma cells which promotes vemurafenib resistance
by: Jianyu Peng, et al.
Published: (2023-07-01)

Polyamine-Based Nanostructures Share Polyamine Transport Mechanisms with Native Polyamines and Their Analogues: Significance for Polyamine-Targeted Therapy
by: Cassandra E. Holbert, et al.
Published: (2022-08-01)

Eruptive Nevi Mimicking Wart-Like Lesions under Selective BRAF Inhibition in a 37-Year-Old Female Melanoma Patient
by: Laurenz Schmitt, et al.
Published: (2013-03-01)

Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
by: Ottavia Bernocchi, et al.
Published: (2021-02-01)

The hypusine pathway in Ixodes ricinus: molecular cloning and validation of deoxyhypusine synthase as a novel target for drug discovery to treat and prevent vector borne diseases
by: Annette Kaiser, et al.
Published: (2025-08-01)

Spermidine enhances steroidogenesis by elevating eIF5Ahyp level in hierarchical follicular granulosa cells of the goose
by: Dongmei Jiang, et al.
Published: (2025-10-01)

Acquired and intrinsic resistance to vemurafenib in BRAFV600E‐driven melanoma brain metastases
by: Ping Zhang, et al.
Published: (2024-01-01)

Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University
by: Kata Ferenczi, et al.
Published: (2023-11-01)

Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment
by: Fréderic Franconieri, et al.
Published: (2018-08-01)

TMTP1‐Modified Small Extracellular Vesicles Target BRAF Mutation in Anaplastic Thyroid Cancer Reversing Vemurafenib Resistance With CRISPR/Cas9 Delivery
by: Shuo Zhang, et al.
Published: (2025-09-01)

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS
by: I. S. Krysanov, et al.
Published: (2022-07-01)

Improvement of Neurodegenerative Disease after Use of Vemurafenib in Refractory BRAF V600E-Mutated Langerhans Cell Histiocytosis: A Case Report
by: Young Kwon Koh, et al.
Published: (2022-10-01)

Transcriptional and Translational Dynamics of Zika and Dengue Virus Infection
by: Kamini Singh, et al.
Published: (2022-06-01)